stars 1 stars 2 stars 3

SYnAbs' mission is to generate innovative antibodies against poor immunogenic compounds (steroids, small molecules, carbohydrates, epigenetic modifications) and complex antigens (GPCR, ion channels, toxins, transporters, proteins from viral envelopes) thanks to unique technologies (DNA immunization, syngeneic cell immunization, rat-LOU species). Anti-drug antibodies, surrogates, or therapeutics mAbs one-stop-shop solution from antigen to gr manufacturing.

SYnAbs Questions

The SYnAbs annual revenue was $11 million in 2026.

Julien Isoard is the Chairman and CEO of SYnAbs.

6 people are employed at SYnAbs.

SYnAbs is based in Charleroi, Walloon Region.

The NAICS codes for SYnAbs are [5417, 54, 541, 541713, 54171].

The SIC codes for SYnAbs are [87, 873].

Top SYnAbs Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users